One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes.

Taybani ZJ, Bótyik B, Gyimesi A, Katkó M, Várkonyi T

Endocrinology, diabetes & metabolism3 Dec 2022Cited by 11 (Europe PMC)

PMID36461758PMCIDPMC9836254DOI10.1002/edm2.390PepBankPUB-36461758

Summary

IntroductionThis study aimed to investigate the sustained safety and efficacy of insulin treatment simplification with IDegLira in patients with type 2 diabetes and an HbA1c ≤ 7.5% (58 mmol/mol) during a 12-month follow-up.MethodsSeventy-two adults with type 2 diabetes and an HbA1c ≤ 7.5% (58 mmol/mol) treated with multiple daily insulin injections (MDI) participated in the trial (age 63.8 ± 9.5 years, HbA1c 6.4 ± 0.7%, [46 ± 8 mmol/mol] body weight 92.95 ± 18.83 kg, total daily insulin dose: 43.21 ± 10.80 units; mean ± SD). Previous insulins were stopped, and once daily IDegLira was started. IDegLira was titrated by the patients to achieve a self-measured prebreakfast plasma glucose concentration of ≥5 mmol/L to ≤6 mmol/L.ResultsAfter 12 months, good glycaemic control was maintained, while body weight decreased significantly. Mean HbA1c changed to 6.2 ± 0.8% (44 ± 9 mmol/mol) (p = .109) and body weight changed by -3.89 kg to 89.06 ± 18.61 kg (p < .0001). The simplified treatment was safe and well-tolerated. Percentage of patients experiencing at least one episode of hypoglycaemia was 49% during the month before simplification and 17% during the last 3 months of the follow-up.ConclusionsInsulin treatment simplification with IDegLira in selected patients with type 2 diabetes is safe, maintains adequate glycaemic control and is associated with weight loss over 12 months.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, switching from multiple daily insulin injections to IDegLira kept HbA1c unchanged at 12 months.
In plain wordsIn adults with type 2 diabetes, switching to a combined insulin-plus-GLP-1 product (IDegLira) kept blood sugar control steady for 12 months.
Peptide
Liraglutide
Outcome
No significant changeHbA1c change at 12 months
Study
n = 72
Comparator
Baseline on multiple daily insulin injections
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c
6.2%
12 months
Source sentences
Summary
Mean HbA1c changed to 6.2 ± 0.8% (44 ± 9 mmol/mol) (p = .109) and body weight changed by -3.89 kg to 89.06 ± 18.61 kg (p < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-two adults with type 2 diabetes and an HbA1c ≤ 7.5% (58 mmol/mol) treated with multiple daily insulin injections (MDI) participated in the trial (age 63.8 ± 9.5 years, HbA1c 6.4 ± 0.7%, [46 ± 8 mmol/mol] body weight 92.95 ± 18.83 kg, total daily insulin dose: 43.21 ± 10.80 units; mean ± SD).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3646175801
02HumanNot a test of Liraglutide aloneNon-randomized trialEfficacy outcome
In adults with type 2 diabetes, switching to IDegLira (insulin degludec plus liraglutide) lowered body weight significantly at 12 months.
In plain wordsIn adults with type 2 diabetes, switching to a combined insulin-plus-GLP-1 product (IDegLira) was followed by weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight change at 12 months
Study
n = 72
Comparator
Baseline on multiple daily insulin injections
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−3.89 kg
12 months
Source sentences
Summary
Mean HbA1c changed to 6.2 ± 0.8% (44 ± 9 mmol/mol) (p = .109) and body weight changed by -3.89 kg to 89.06 ± 18.61 kg (p < .0001).
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-two adults with type 2 diabetes and an HbA1c ≤ 7.5% (58 mmol/mol) treated with multiple daily insulin injections (MDI) participated in the trial (age 63.8 ± 9.5 years, HbA1c 6.4 ± 0.7%, [46 ± 8 mmol/mol] body weight 92.95 ± 18.83 kg, total daily insulin dose: 43.21 ± 10.80 units; mean ± SD).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3646175802
03HumanNot a test of Liraglutide aloneNon-randomized trialSafety outcome
In adults with type 2 diabetes, the share of patients with at least one hypoglycaemia episode fell from 49% before simplification to 17% in the last 3 months on IDegLira.
In plain wordsIn adults with type 2 diabetes, fewer patients had low blood sugar episodes on IDegLira (17%) than before the switch (49%).
Peptide
Liraglutide
Outcome
DecreasePatients with at least one hypoglycaemia episode
Study
n = 72
Comparator
Baseline on multiple daily insulin injections
Outcome group
Adverse events · Metabolic and weight
Measurements
Patients with hypoglycaemia
49%
month before simplification
Patients with hypoglycaemia
17%
last 3 months of follow-up
Source sentences
Summary
Percentage of patients experiencing at least one episode of hypoglycaemia was 49% during the month before simplification and 17% during the last 3 months of the follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
Seventy-two adults with type 2 diabetes and an HbA1c ≤ 7.5% (58 mmol/mol) treated with multiple daily insulin injections (MDI) participated in the trial (age 63.8 ± 9.5 years, HbA1c 6.4 ± 0.7%, [46 ± 8 mmol/mol] body weight 92.95 ± 18.83 kg, total daily insulin dose: 43.21 ± 10.80 units; mean ± SD).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3646175803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.